Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study

Isabelle Häberling, Gregor Berger, Klaus Schmeck, Ulrike Held, Susanne Walitza, Isabelle Häberling, Gregor Berger, Klaus Schmeck, Ulrike Held, Susanne Walitza

Abstract

Background: Depressive disorders in childhood and adolescence are a major health problem and often follow a chronic course with severe consequences in later life. Depressive disorders cause the highest burden of disease in this age group across all medical conditions. Treatment adherence is usually very poor, and the use of antidepressant drugs is heavily debated, as suicidal ideations may increase, in particular in the early phase of treatment. Omega-3 fatty acids rich in eicosapentaenoic acid have shown some promising results in over a dozen small scale randomized controlled trials (RCTs) in adult major depressive disorders, with only very few published RCTs in children and adolescents. High-quality phase III RCTs are missing. Methods and Design: The omega-3-pMDD trial is a carefully designed phase III RCT to assess the efficacy and safety of omega-3 fatty acids in the early course of pediatric major depressive disorder (MDD). The study is designed as a multi-center, double-blinded, placebo-controlled, randomized clinical trial enrolling 220 patients aged 8 to 17 years meeting DSM-IV criteria for major depressive disorder of at least moderate symptom severity. After a single-blinded placebo-lead-in phase (7 to 10 days) patients are randomly assigned to omega-3 fatty acids or placebo over 36 weeks. Primary outcomes are changes in depression severity, as well as remission and recovery rates. Secondary outcome measures include the omega-3 index and inflammatory parameters as predictors of response. Data analysis will be performed in the intention-to-treat sample using a (generalized) linear random intercept regression model. Through sampling of blood, hair, saliva, and urine, further putative biological markers for depression and omega-3 fatty response will be investigated. Discussion: This trial addresses if omega-3 fatty acids play a role in the pathogenesis of pediatric MDDs and have antidepressant properties, in particular in clinically depressed children and adolescents with a pre-existing omega-3 fatty acid deficiency, increased markers of oxidative stress, and/or markers of (low grade) inflammation. Ethics and Dissemination: The study was approved by the local ethics committees. The results will be published in peer-reviewed journals irrespective of specific outcomes. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03167307.

Keywords: clinical trial protocol; omega-3 fatty acids; pediatric depression; randomized controlled trial; treatment of depression.

Copyright © 2019 Häberling, Berger, Schmeck, Held and Walitza.

Figures

Figure 1
Figure 1
Flowchart study schedule Omega-3-pMDD trial.

References

    1. Avenevoli S, Swendsen J, He JP, Burstein M, Merikangas KR. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry (2015) 5437-44(1):e32. 10.1016/j.jaac.2014.10.010
    1. Breslau J, Gilman SE, Stein BD, Ruder T, Gmelin T, Miller E. Sex differences in recent first-onset depression in an epidemiological sample of adolescents. Transl Psychiatry (2017) 7(5):e1139. 10.1038/tp.2017.105
    1. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry (1996) 35(6):705–15. 10.1097/00004583-199606000-00010
    1. Kaminski KM, Garber J. Depressive spectrum disorders in high-risk adolescents: episode duration and predictors of time to recovery. J Am Acad Child Adolesc Psychiatry (2002) 41(4):410–8. 10.1097/00004583-200204000-00013
    1. Lewinsohn PM, Rohde P, Seeley JR, Klein DN, Gotlib IH. Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry (2000) 157(10):1584–91. 10.1176/appi.ajp.157.10.1584
    1. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry (2002) 59(3):225–31. 10.1001/archpsyc.59.3.225
    1. Korczak DJ, Goldstein BI. Childhood onset major depressive disorder: course of illness and psychiatric comorbidity in a community sample. J Pediatr (2009) 155(1):118–23. 10.1016/j.jpeds.2009.01.061
    1. Ferrari AJ, Norman RE, Freedman G, Baxter AJ, Pirkis JE, Harris MG, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PloS One (2014) 9(4):e91936. 10.1371/journal.pone.0091936
    1. Richardson LP, Ludman E, McCauley E, Lindenbaum J, Larison C, Zhou C, et al. Collaborative care for adolescents with depression in primary care: a randomized clinical trial. JAMA (2014) 312(8):809–16. 10.1001/jama.2014.9259
    1. Scott EG, Luxmore B, Alexander H, Fenn RL, Christopher NC. Screening for adolescent depression in a pediatric emergency department. Acad Emerg Med (2006) 13(5):537–42. 10.1197/j.aem.2005.11.085
    1. Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord (2014), 152–4:45–51. 10.1016/j.jad.2013.10.002
    1. Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet (2011) 377(9783):2093–102. 10.1016/S0140-6736(11)60512-6
    1. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol (2011) 44(2):203–15. 10.1007/s12035-010-8162-0
    1. Hibbeln JR. Fish consumption and major depression. Lancet (1998) 351(9110):1213. 10.1016/S0140-6736(05)79168-6
    1. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord (2004) 82(3):447–52. 10.1016/j.jad.2004.02.002
    1. Murakami K, Miyake Y, Sasaki S, Tanaka K, Arakawa M. Fish and n-3 polyunsaturated fatty acid intake and depressive symptoms: Ryukyus Child Health Study. Pediatrics (2010) 126(3):e623–630. 10.1542/peds.2009-3277
    1. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry (2010) 68(2):140–7. 10.1016/j.biopsych.2010.03.018
    1. Carney RM, Steinmeyer BC, Freedland KE, Rubin EH, Rich MW, Harris WS. Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. J Clin Psychiatry (2016) 77(2):e138–143. 10.4088/JCP.14m09660
    1. Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx B. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology (2018) 87:53–62. 10.1016/j.psyneuen.2017.10.005
    1. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr (2006) 84(6):1308–16. 10.1093/ajcn/84.6.1308
    1. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry (2007) 68(7):1056–61. 10.4088/jcp.v68n0712
    1. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr (2009) 28(5):525–42. 10.1080/07315724.2009.10719785
    1. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr (2010) 91(3):757–70. 10.3945/ajcn.2009.28313
    1. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry (2011. a) 72(12):1577–84. 10.4088/JCP.10m06634
    1. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry (2012) 17(12):1272–82. 10.1038/mp.2011.100
    1. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PloS One (2014. b) 9(5):e96905. 10.1371/journal.pone.0096905
    1. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. omega-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open (2016) 6(3):e010172. 10.1136/bmjopen-2015-010172
    1. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry (2016. b) 209(3):192–201. 10.1192/bjp.bp.114.160242
    1. Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhe HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry (2016. a) 6:e756. 10.1038/tp.2016.29
    1. Schefft C, Kilarski LL, Bschor T, Kohler S. Efficacy of adding nutritional supplements in unipolar depression: a systematic review and meta-analysis. Eur Neuropsychopharmacol (2017) 27(11):1090–109. 10.1016/j.euroneuro.2017.07.004
    1. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry (2008) 42(3):192–8. 10.1080/00048670701827275
    1. Pottala JV, Talley JA, Churchill SW, Lynch DA, von Schacky C, Harris WS. Red blood cell fatty acids are associated with depression in a case-control study of adolescents. Prostaglandins Leukot Essent Fatty Acids (2012) 86(4-5):161–5. 10.1016/j.plefa.2012.03.002
    1. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry (2006) 163(6):1098–100. 10.1176/ajp.2006.163.6.1098
    1. Ginty AT, Conklin SM. Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial. Psychiatry Res (2015) 229(1-2):485–9. 10.1016/j.psychres.2015.05.072
    1. Trebaticka J, Hradecna Z, Bohmer F, Vavakova M, Waczulikova I, Garaiova I, et al. Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents: a pilot study. Child Adolesc Psychiatry Ment Health (2017) 11:30. 10.1186/s13034-017-0167-2
    1. Fristad MA, Vesco AT, Young AS, Healy KZ, Nader ES, Gardner W, et al. Pilot randomized controlled trial of Omega-3 and individual-family psychoeducational psychotherapy for children and adolescents with depression. J Clin Child Adolesc Psychol (2019) 48(sup1):S105–18. 10.1080/15374416.2016.1233500
    1. McNamara RK, Strimpfel J, Jandacek R, Rider T, Tso P, Welge JA, et al. Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder. Pharma Nutr (2014) 2(2):38–46. 10.1016/j.phanu.2014.02.002
    1. Gabbay V, Freed RD, Alonso CM, Senger S, Stadterman J, Davison BA, et al. A double-blind placebo-controlled trial of Omega-3 fatty acids as a monotherapy for adolescent depression. J Clin Psychiatry (2018) 79(4). 10.4088/JCP.17m11596
    1. Bortolato B, Miskowiak KW, Kohler CA, Maes M, Fernandes BS, Berk M, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med (2016) 14:9. 10.1186/s12916-016-0560-3
    1. MacQueen GM, Memedovich KA. Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options. Psychiatry Clin Neurosci (2017) 71(1):18–27. 10.1111/pcn.12463
    1. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr (2012) 107(11):1682–93. 10.1017/S0007114511004788
    1. Samieri C, Feart C, Proust-Lima C, Peuchant E, Dartigues JF, Amieva H, et al. omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging (2011) 322317(12):e2313–2322. 10.1016/j.neurobiolaging.2010.03.020
    1. Antypa N, Van der Does AJ, Smelt AH, Rogers RD. Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers. J Psychopharmacol (2009) 23(7):831–40. 10.1177/0269881108092120
    1. Mazereeuw G, Herrmann N, Oh PI, Ma DW, Wang CT, Kiss A, et al. Omega-3 fatty acids, depressive symptoms, and cognitive performance in patients with coronary artery disease: analyses from a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol (2016) 36(5):436–44. 10.1097/JCP.0000000000000565
    1. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest (2005) 35(11):691–9. 10.1111/j.1365-2362.2005.01570.x
    1. Sorensen LB, Damsgaard CT, Dalskov SM, Petersen RA, Egelund N, Dyssegaard CB, et al. Diet-induced changes in iron and n-3 fatty acid status and associations with cognitive performance in 8-11-year-old Danish children: secondary analyses of the optimal well-being, development and health for Danish children through a healthy new Nordic diet school meal study. Br J Nutr (2015) 114(10):1623–37. 10.1017/S0007114515003323
    1. de Groot RH, Ouwehand C, Jolles J. Eating the right amount of fish: inverted U-shape association between fish consumption and cognitive performance and academic achievement in Dutch adolescents. Prostaglandins Leukot Essent Fatty Acids (2012) 86(3):113–7. 10.1016/j.plefa.2012.01.002
    1. van der Wurff IS, von Schacky C, Berge K, Zeegers MP, Kirschner PA, de Groot RH. Association between blood Omega-3 index and cognition in typically developing Dutch adolescents. Nutrients (2016) 8(1). 10.3390/nu8010013
    1. Jiao J, Li Q, Chu J, Zeng W, Yang M, Zhu S. Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr (2014) 100(6):1422–36. 10.3945/ajcn.114.095315
    1. Nelson EB, Van Elswyk ME. Limitations of the review and meta-analysis of the role of n-3 long-chain PUFA supplementation and cognitive function. Am J Clin Nutr (2015) 101(6):1305–6. 10.3945/ajcn.115.107078
    1. Widenhorn-Muller K, Schwanda S, Scholz E, Spitzer M, Bode H. Effect of supplementation with long-chain omega-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukot Essent Fatty Acids (2014) 91(1-2):49–60. 10.1016/j.plefa.2014.04.004
    1. Milte CM, Sinn N, Buckley JD, Coates AM, Young RM, Howe PR. Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J Child Health Care (2011) 15(4):299–311. 10.1177/1367493511403953
    1. Chang JP, Su KP, Mondelli V, Pariante CM. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology (2018. b) 43(3):534–45. 10.1038/npp.2017.160
    1. Vesco AT, Young AS, Arnold LE, Fristad MA. Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials. J Child Psychol Psychiatry (2018) 59(6):628–36. 10.1111/jcpp.12830
    1. Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, et al. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxid Med Cell Longev (2014. a) 2014:313570. 10.1155/2014/313570
    1. Song C, Li X, Kang Z, Kadotomi Y. Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology (2007) 32(3):736–44. 10.1038/sj.npp.1301117
    1. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry (2008) 13(7):717–28. 10.1038/sj.mp.4002055
    1. Larrieu T, Hilal ML, Fourrier C, De Smedt-Peyrusse V, Sans N, Capuron L, et al. Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl Psychiatry (2014) 4:e437. 10.1038/tp.2014.77
    1. Mocking RJ, Ruhe HG, Assies J, Lok A, Koeter MW, Visser I. Relationship between the hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in recurrent depression. Psychoneuroendocrinology (2013) 38(9):1607–17. 10.1016/j.psyneuen.2013.01.013
    1. Mocking RJ, Verburg HF, Westerink AM, Assies J, Vaz FM, Koeter MW, et al. Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: associations with prospective antidepressant response. Psychoneuroendocrinology (2015) 59:1–13. 10.1016/j.psyneuen.2015.04.027
    1. Logan AC. Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis (2004) 3:25. 10.1186/1476-511X-3-25
    1. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry (2010) 167(11):1305–20. 10.1176/appi.ajp.2009.10030434
    1. Wager-Smith K, Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev (2011) 35(3):742–64. 10.1016/j.neubiorev.2010.09.010
    1. DeFilippis AP, Sperling LS. Understanding omega-3’s. Am Heart J (2006) 151(3):564–70. 10.1016/j.ahj.2005.03.051
    1. Owen C, Rees AM, Parker G. The role of fatty acids in the development and treatment of mood disorders. Curr Opin Psychiatry (2008) 21(1):19–24. 10.1097/YCO.0b013e3282f29841
    1. Maes M, Mihaylova I, Kubera M, Bosmans E. Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro Endocrinol Lett (2007) 28(6):875–80.
    1. Muller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders–relation to drug treatment. Dialogues Clin Neurosci (2009) 11(3):319–32.
    1. Freeman MP, Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care. J Clin Psychiatry (2011) 72(2):258–9. 10.4088/JCP.11ac06830
    1. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry (2006) 163(6):969–78. 10.1176/ajp.2006.163.6.969
    1. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med (2003) 65(3):362–8. 10.1097/01.psy.0000035719.79068.2b
    1. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev (2003) 8(4):410–25.
    1. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry (2000) 157(1):115–8. 10.1176/ajp.157.1.115
    1. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids (2006) 75(4-5):329–49. 10.1016/j.plefa.2006.07.010
    1. McNamara RK, Vannest JJ, Valentine CJ. Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: mechanisms and implications for psychopathology. World J Psychiatry (2015) 5(1):15–34. 10.5498/wjp.v5.i1.15
    1. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging (2004) 8(3):163–74.
    1. Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res (2014) 53:1–17. 10.1016/j.plipres.2013.10.002
    1. Pudell C, Vicente BA, Delattre AM, Carabelli B, Mori MA, Suchecki D, et al. Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats. Eur J Neurosci (2014) 39(2):266–74. 10.1111/ejn.12406
    1. Carlezon WA, Jr., Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry (2005) 57(4):343–50. 10.1016/j.biopsych.2004.11.038
    1. Huang SY, Yang HT, Chiu CC, Pariante CM, Su KP. Omega-3 fatty acids on the forced-swimming test. J Psychiatr Res (2008) 42(1):58–63. 10.1016/j.jpsychires.2006.09.004
    1. Song C, Zhang XY, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci (2009) 29(1):14–22. 10.1523/JNEUROSCI.3569-08.2009
    1. Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35(3):760–8. 10.1016/j.pnpbp.2010.06.020
    1. Bartl J, Walitza S, Grunblatt E. Enhancement of cell viability after treatment with polyunsaturated fatty acids. Neurosci Lett (2014) 559:56–60. 10.1016/j.neulet.2013.11.023
    1. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem (1996) 66(4):1582–91. 10.1046/j.1471-4159.1996.66041582.x
    1. Delion S, Chalon S, Guilloteau D, Lejeune B, Besnard JC, Durand G. Age-related changes in phospholipid fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet. J Lipid Res (1997) 38(4):680–9.
    1. Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, Besnard JC, et al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res (2000) 41(1):32–40.
    1. Song C, Horrobin D. Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration. J Lipid Res (2004) 45(6):1112–21. 10.1194/jlr.M300526-JLR200
    1. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids (2004) 71(3):171–6. 10.1016/j.plefa.2004.03.011
    1. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids (2006) 75(4-5):259–69. 10.1016/j.plefa.2006.07.005
    1. McNamara RK, Able J, Liu Y, Jandacek R, Rider T, Tso P, et al. Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects. J Psychiatr Res (2009) 43(6):656–63. 10.1016/j.jpsychires.2008.09.011
    1. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N., Jr Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry (1998. a) 44(4):235–42. 10.1016/s0006-3223(98)00141-3
    1. Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, et al. A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biol Psychiatry (1998. b) 44(4):243–9. 10.1016/s0006-3223(98)00143-7
    1. Litman BJ, Niu SL, Polozova A, Mitchell DC. The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction. J Mol Neurosci (2001) 16(2-3):237–42. 10.1385/JMN:16:2-3:237discussion279-284.
    1. Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci U.S.A. (2006) 103(13):4888–93. 10.1073/pnas.0508352103
    1. Bowen RA, Clandinin MT. Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipid fatty acid composition and sodium-potassium ATPase kinetics in developing rats. J Neurochem (2002) 83(4):764–74. 10.1046/j.1471-4159.2002.01156.x
    1. Said T, Tremblay-Mercier J, Berrougui H, Rat P, Khalil A. Effects of vegetable oils on biochemical and biophysical properties of membrane retinal pigment epithelium cells. Can J Physiol Pharmacol (2013) 91(10):812–7. 10.1139/cjpp-2013-0036
    1. Joyce NR, Schuler MS, Hadland SE, Hatfield LA. Variation in the 12-month treatment trajectories of children and adolescents after a diagnosis of depression. JAMA Pediatr (2018) 172(1):49–56. 10.1001/jamapediatrics.2017.3808
    1. Newman TB. A black-box warning for antidepressants in children? N Engl J Med (2004) 351(16):1595–8. 10.1056/NEJMp048279
    1. Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ (2016) 352:i65. 10.1136/bmj.i65
    1. Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 69(6):580–7. 10.1001/archgenpsychiatry.2011.2048
    1. Barry CL, Busch SH. News coverage of FDA warnings on pediatric antidepressant use and suicidality. Pediatrics (2010) 125(1):88–95. 10.1542/peds.2009-0792
    1. Poznanski EO, Cook SC, Carroll BJ. A depression rating scale for children. Pediatrics (1979) 64(4):442–50.
    1. Poznanski E, Mokros H. Children’s Depression Rating Scale-Revised (CDRS-R). Los Angeles:WPS; (1996).
    1. Grosso G, Micek A, Marventano S, Castellano S, Mistretta A, Pajak A, et al. Dietary n-3 PUFA, fish consumption and depression: a systematic review and meta-analysis of observational studies. J Affect Disord (2016) 205:269–81. 10.1016/j.jad.2016.08.011
    1. Damico KE, Stoll AL, Marangell LB, Cohen BM. How blind is double-blind? A study of fish oil versus placebo. Prostaglandins Leukot Essent Fatty Acids (2002) 66(4):393–5. 10.1054/plef.2002.0364
    1. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, et al. (Hrsg) für die Leitliniengruppe Unipolare Depression*. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 1 Auflage. Version 5 (2009). 10.6101/AZQ/000239
    1. Jeansen S, Witkamp RF, Garthoff JA, van Helvoort A, Calder PC. Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: analysis of 8 clinical studies with selected patient groups on omega-3-enriched medical nutrition. Clin Nutr (2018) 37(3):948–57. 10.1016/j.clnu.2017.03.027
    1. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry (2010) 197(5):372–7. 10.1192/bjp.bp.109.076430
    1. Azar R, Nolan RP, Stewart DE. Listening to the heart-brain talk: persistent depressive symptoms are associated with hsCRP in apparently healthy individuals at high risk for coronary artery disease. Eur J Prev Cardiol (2012) 19(4):857–63. 10.1177/1741826711415720
    1. Duivis HE, Kupper N, Vermunt JK, Penninx BW, Bosch NM, Riese H, et al. Depression trajectories, inflammation, and lifestyle factors in adolescence: The TRacking Adolescents’ Individual Lives Survey. Health Psychol (2015) 34(11):1047–57. 10.1037/hea0000210
    1. Plener PL, Grieb J, Sprober N, Straub J, Schneider A, Keller F, et al. Convergence of children’s depression rating scale-revised scores and clinical diagnosis in rating adolescent depressive symptomatology. Ment Illn (2012) 4(1):e7. 10.4081/mi.2012.e7
    1. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry (2007) 64(10):1132–43. 10.1001/archpsyc.64.10.1132
    1. Keller F, Grieb J, Ernst M, Sprober N, Fegert JM, Kolch M. [Children’s Depression Rating Scale-Revised (CDRS-R): development of a German version and psychometric properties in a clinical sample]. Z Kinder Jugendpsychiatr Psychother (2011) 39(3):179–85. 10.1024/1422-4917/a000090
    1. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2002) 41(10):1205–15. 10.1097/00004583-200210000-00010
    1. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry (1997) 36(7):980–8. 10.1097/00004583-199707000-00021
    1. Stiensmeier-Pelster JM, Schürmann M, Duda K. Depressions-Inventar für Kinder und Jugendliche (DIKJ). Handanweisung (2., überarb. und neunormierte Auflage). Göttingen:Hogrefe; (2000).
    1. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol (1974) 42(6):861–5. 10.1037/h0037562
    1. Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. J Anxiety Disord (2006) 20(4):444–58. 10.1016/j.janxdis.2005.05.004
    1. Reynolds W. SIQ, Suicidal Ideation Questionnaire: Professional Manual. Florida: Psychological Assessment Resources; (1998).
    1. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med (2001) 2(4):297–307. 10.1016/s1389-9457(00)00065-4
    1. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety (2003) 18(2):76–82. 10.1002/da.10113
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav (1983) 24(4):385–96.
    1. Ravens-Sieberer U, Gosch A, Rajmil L, Erhart M, Bruil J, Power M, et al. The KIDSCREEN-52 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. Value Health (2008) 11(4):645–58. 10.1111/j.1524-4733.2007.00291.x
    1. Goodman R, Meltzer H, Bailey V. The strengths and difficulties questionnaire: a pilot study on the validity of the self-report version. Eur Child Adolesc Psychiatry (1998) 7(3):125–30. 10.1007/s007870050057
    1. Kröger C, del Pozo MA, Kosfelder J, Allroggen M, Grabowski G, Legenbauer T. Erfassung von Impulsivität und emotionaler Dysregulation bei Jugendlichen mit Borderline-Persönlichkeitsstörung. Diagnostica (2017) 63(4):297–308. 10.1026/0012-1924/a000184
    1. Guy W. Clinical Global Impression (CGI) Scale, Modified. Washington DC:American Psychiatric Association; (2000).
    1. Schaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry (1983) 40:1228–31. 10.1001/archpsyc.1983.01790100074010
    1. Gowers SG, Harrington RC, Whitton A, Lelliott P, Beevor A, Wing J, et al. Brief scale for measuring the outcomes of emotional and behavioural disorders in children. Health of the Nation Outcome Scales for children and Adolescents (HoNOSCA). Br J Psychiatry (1999) 174:413–6. 10.1192/bjp.174.5.413
    1. Gioia GA, Isquith PK, Guy SC, Kenworthy L. BRIEF: Behavior rating inventory of executive function. Lutz, FL:Psychological Assessment Resources; (2000).
    1. Helmstadter C, Lendt M, Lux S. Verbaler Lern- und Merkfähigkeitstest: VLMT, Manual. Gottingen:Beltz Test GmbH; (2001).
    1. Wechsler D. Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV). San Antonio, TX:The Psychological Corporation; (2003).
    1. de Sonneville L. Amsterdam Neuropsychological Tasks: A computer-aided assessment program. Cogn Ergon Clin Asses Comput Assist Learn: Comput In Psychol (1999) 6:187–203.
    1. Aschenbrenner S, Tucha O, Lange KW. Regensuberger Wortflüssigkeits-Test: RWT. Göttingen:Hogrefe; (2000).
    1. Reynolds R, Kamphaus C. Reynolds Intellectual Assessment Scales and Reynolds Intellectual Screening Test Professional Manual. Lutz, FL: Psychological Assessment Resources (2003).
    1. Hodgson K, Uher R, Crawford AA, Lewis G, O’Donovan MC, Keers R, et al. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Psychopharmacol (2014) 28(2):142–50. 10.1177/0269881113517957
    1. Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract (2010) 16(3):574–9. 10.1111/j.1365-2753.2009.01169.x
    1. Sublette ME, Segal-Isaacson CJ, Cooper TB, Fekri S, Vanegas N, Galfalvy HC, et al. Validation of a food frequency questionnaire to assess intake of n-3 polyunsaturated fatty acids in subjects with and without major depressive disorder. J Am Diet Assoc (2011. b) 111(1):117–123 e111-112. 10.1016/j.jada.2010.10.007
    1. Marshall WA, Tanner JM.Variations in the pattern of pubertal changes in boys. Arch Dis Child (1970) 45(239):13–23. 10.1136/adc.45.239.13
    1. Bernstein DP, Ahluvalia T, Pogge D, Handelsman L. Validity of the Childhood Trauma Questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry (1997) 36(3):340–8. 10.1097/00004583-199703000-00012
    1. Olweus D. The Revised Olweus Bully/Victim Questionnaire. Bergern, Norway:Mimeo, Research Center of Health Promotion (HEMIL), University of Bergen; (1996).
    1. Drechsler R, Steinhausen H-C. Verhaltensinventar zur Beurteilung exekutiver Funktionen BRIEF. Deutschsprachige Adaption des Behavior Rating Inventory of Executive Function. Bern:Verlag Hans Huber; (2013).
    1. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA.Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry (2009) 166(1):42–9. 10.1176/appi.ajp.2008.08020247
    1. Parellada M, Moreno C, Moreno M, Espliego A, de Portugal E, Arango C. Placebo effect in child and adolescent psychiatric trials. Eur Neuropsychopharmacol (2012) 22(11):787–99. 10.1016/j.euroneuro.2011.09.007
    1. Treatment for Adolescents With Depression Study, T..Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry (2003) 42(5):531–42. 10.1097/01.CHI.0000046839.90931.0D
    1. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J psychiatry: J Ment Sci (2016. a) 209(3):192–201. 10.1192/bjp.bp.114.160242
    1. Mocking RJT, Harmsen I, Assies J, Koeter MWJ, Ruhe HG, Schene AH.Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Trans Psychiatry (2016. b) 6:e756. 10.1038/tp.2016.29
    1. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramaniapillai M.Efficacy of omega-3 PUFAs in depression: a meta-analysis. Trans Psychiatry (2019) 9(1):190. 10.1038/s41398-019-0515-5
    1. Jolani S, Frank LE, van Buuren S.Dual imputation model for incomplete longitudinal data. Br J Math Stat Psychol (2014) 67(2):197–212. 10.1111/bmsp.12021
    1. Chang CH, Tseng PT, Chen NY, Lin PC, Lin PY, Chang JP, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids (2018. a) 129:1–12. 10.1016/j.plefa.2018.01.001
    1. Corrigan PW, Morris SB, Michaels PJ, Rafacz JD, Rusch N. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. Psychiatr Serv (2012) 63(10):963–73. 10.1176/appi.ps.201100529
    1. Hulvershorn LA, Cullen K, Anand A. Toward dysfunctional connectivity: a review of neuroimaging findings in pediatric major depressive disorder. Brain Imaging Behav (2011) 5(4):307–28. 10.1007/s11682-011-9134-3

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever